General Information of Drug (ID: DM104SP)

Drug Name
Vericigiuat Drug Info
Indication
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM104SP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cinaciguat DMGEAM6 Acute decompensated heart failure BD1Z Phase 2 [3]
RIG-200 DMLQD6F Hypertension BA00-BA04 Discontinued in Phase 1 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Guanylate cyclase soluble beta-1 (GUCY1B1) TTLBYH1 GCYB1_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of Bayer HealthCare Pharmaceuticals.
2 Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38.
3 Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009 Jun 2;119(21):2781-8.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015